Master Session: Cervix Cancer

• Chairs: Bradley Monk (USA), Mary McCormack (UK), Ana Oaknin (Spain)
• Histologic Subtypes & Molecular Features: Kathleen Moore (USA)
• Staging: Jalid Sehouli (Germany)
• State of the Science in Radiation Therapy: Alexandra Taylor (UK)
• Addition Systemic Therapy to Radiation (CCRT): Linda Mileshkin (Australia)
• Firstline Treatment of Metastatic Disease: Leslie Randall (USA)
• Second-Line Metastatic Disease: Krishnansu Tewari (USA)
• Clinical Care in Under-Resourced Settings & How To Start A Clinical Trials Program: Marie Plante (Canada)

Master Session: Vulvar Cancer

• Chairs: Michael Höckel (Germany), Benedetti Panici (Italy), Ate van der Zee (The Netherlands)
• Current Insights in the Etiology & Pathogenesis of Vulvar Cancer: HPV Infection - Predisposing Conditions - Premalignant Disease - Overt Malignancy: Joanne de Hullu (The Netherlands)
• Debate: Early Stage Vulvar Cancer: An Overview of Current Standard of Surgical Care vs Cancer Field Surgery for Vulvar Carcinoma as Alternative Approach: Maaike Oonk (The Netherlands) vs Nadja Dornhöfer (Germany)
• Role of Adjuvant Therapy in Primary Treatment of Vulvar Cancer: Linn Wölber (Germany)

Plenary I: Oral Abstract Presentations

• Moderator: Nicoletta Colombo (Italy)
• Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial: Jonathan Ledermann (United Kingdom)
• Efficacy and Safety of Lenvatinib Plus Pembrolizumab in Patients with Previously Treated Ovarian Cancer in the Multicohort Phase 2 LEAP-005 Study: Antonio González-Martín (Spain)
• Postprogression Efficacy Outcomes From the Phase 3 ARIEL3 Study of Rucaparib in Patients With Platinum-Sensitive Recurrent Ovarian Carcinoma Associated With Either BRCA1 or BRCA2 Mutations: Johanne Weberpals (Canada)
• Distillation: Kathleen Moore (USA)

Plenary II: Oral Abstracts Presentations

• Moderators: Matthew Powell (USA), Rene Pareja (Colombia)
• Refining Pathologic Interpretation of Endometrial Carcinomas: Lessons Learned from a Nationwide Study in a new Era of Molecular Classification: Emily Thompson (Canada)
• Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study: Soyoun Rachel Kim (Canada)
• Variation in practice in endometrial cancer (EC); can molecular classification direct care and reduce costs associated with management?: Emily Thompson (Canada)
• Sentinel lymph node biopsy versus lymphadenectomy for intermediate and high grade endometrial cancer staging (SENTOR trial): A prospective multicenter cohort study: Maria Cusimano (Canada)
• A multicentric randomized trial to evaluate the ROle of uterine MANipulator on laparoscopic/robotic HYsterectomy for the treatment of low-risk endometrial cancer: the ROMANHY Trial (NCT:02762214): Salvatore Gueli Alletti (Italy)
• Frailty is Independently Associated with Worse Outcomes and Increased Resource Use Following Procedures to Treat Endometrial Cancer: Morcos Nakhla (USA)

Plenary III: Oral Abstract Presentations

• Moderators: Paula Wimberger (Germany), Qinglei Gao (China)
• The learning curve of robot-assisted laparoscopy has impact on the oncological outcomes of early stage cervical cancer patients: Isle Baeten (Netherlands)
• Oncologic Outcomes and Role of Adjuvant Therapy in Endometrial Cancer Patients with Low Volume Metastasis in the Sentinel Lymph Nodes: An International Multi-Institutional Study: Andrea Mariani (USA)
• Oncolytic Vaccinia (Olvi-Vec) Primed Immunochemotherapy in Platinum Resistant/Refractory Ovarian Cancer: Robert Holloway (USA)
• Efficacy on Individualized Starting Dose (ISD) and Fixed Starting Dose (FSD) of Niraparib per Investigator-Assessment (IA) in Newly Diagnosed Advanced Ovarian Cancer (OC): Whitney Graybill (USA)
• Distillation: Asima Mukhopadhyay (India)

Presidential Plenary IV

• Presidential Address: Roberto Angioli (Italy)
• World Ovarian Cancer Coalition Global Ovarian Cancer Charter Launch: Elisabeth Baugh (Canada), Frances Reid (UK)
• Global Outreach & Engagement Initiatives of the International Gynecologic Cancer Society: Dicey Jackson Scroggins (USA)
• Business Meeting: Roberto Angioli (Italy)

Plenary V: Oral Abstract Presentations

• Moderators: David Atallah (Lebanon), Andreas Obermair (Australia)
• Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer: Nobumichi Nishikawa (Japan)
• Randomized Double-Blind Placebo Controlled Trial of Frontline Maintenance Vigil Immunotherapy (VITAL study) in Stage III/IV Ovarian Cancer: Efficacy Assessment in BRCA1/2-wt Patients: Rodney Rocconi (USA)
• Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer: Angeles Alvarez Secord (USA)
  Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial: Gilles Freyer (USA)
• Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higherand lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial: Philipp Harter (Germany)